An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event
- First Online:
- 221 Downloads
Cerebrovascular disease (or stroke) is one of the main causes of long-term disability and the second leading cause of death worldwide. The economic impact of stroke is clearly seen, as it is the largest single cause of bed occupancy in hospitals in England and accounts for 6% of hospital costs. This analysis is the first to quantify the economic consequences of a blood pressure lowering regimen based on the PROGRESS study (perindopril-based regimen), for reducing future cardiovascular events.
A Markov decision analytical model was used to estimate the cost per quality adjusted life year (QALY) of blood pressure lowering in the treatment of patients presenting with a cerebrovascular event. The health states are based upon Barthel indices for which resource utilisation and health benefits have previously been estimated.
The participants for the economic analysis were obtained from the PROGRESS study database. 6,105 clinical study participants were recruited through both primary and secondary care centres.
The mean age was 64 years; 70% were male in the original study.
In the PROGRESS study, blood pressure lowering by a perindopril-based regimen was compared to standard care.
Main outcome measures
Cost per quality adjusted life year for the duration of the study (4 years) and for a time span of 20 years.
Using only direct hospital medical costs, the cost per QALY for a perindopril based regimen is £6,927 for the base study period and £10,133 for a 20-year time period. These results are sensitive to the cost of perindopril, the cost of the stroke unit, length of stay, and to a lesser extent, the cost of indapamide.
This analysis demonstrates a cost-effective treatment for patients suffering a cerebrovascular event with a blood pressure lowering regimen. The findings of this study are in line with current decisions and guidance by the national institute for health and clinical excellence (NICE) in England.
KeywordsBlood pressure lowering Cerebrovascular Markov Cost-effectiveness
- 1.World Health Organization.: The World Health Report. WHO, Geneva (1999)Google Scholar
- 3.Wade D.: Stroke. In: Stevens A., Raftery J. (eds.) Health Care Needs Assessment: The Epidemiologically Based Needs Assessment Reviews. Radcliffe Medical Press, Oxford (1994)Google Scholar
- 5.Department of Health: National Service Framework for Coronary Heart Disease. London (2000)Google Scholar
- 6.Office for National Statistics: Mortality Statistics—Causes. London (1997)Google Scholar
- 7.Yuen, P.: OHE Compendium of Health Statistics. Office of Health Economics, London (2004)Google Scholar
- 8.ISD.: Stroke: Incidence and Mortality (2005)Google Scholar
- 9.Wolfe, C., Rudd, A., Beech, R.: Stroke Services and Research. An Overview with Recommendations for Future Research. Stroke Association, London (1996)Google Scholar
- 10.Office of Health Economics: Stroke. Office of Health Economics (1988)Google Scholar
- 11.Chalmers, P.: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Subcommittee. Journal of Hypertension. 17(2), 151–183 (1999)Google Scholar
- 12.Department of Health: National Service Framework for Older People. London (2001)Google Scholar
- 13.Rudd, A., Irwin, P., Rutledge, Z., Lowe, D., Wade, D., Morris, R., Pearson, M.: The national sentinel audit of stroke: a tool for raising standards of care. J. R. Coll. Physicians. 30, 460–464 (1999)Google Scholar
- 14.Guidelines Subcommittee: 1999 World health organization-international society of hypertension guidelines for the management of hypertension. J. Hypertens. 17, 151–183 (1999)Google Scholar
- 19.PROGRESS Management Committee: Blood pressure lowering for the secondary prevention of stroke rationale and design for PROGRESS. J. Hypertens. 14(Suppl 2), S41–S46 (1996)Google Scholar
- 20.MacMahon, S., Peto, R., Cutler, J., Collins, R., Sorlie, P., Neaton, J., Abbott, R., Godwin, J., Dyer, A., Stamler, J.: Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 335, 765–774 (1990)CrossRefGoogle Scholar
- 25.PROGRESS Collaborative Group: Effects of a perindopril-based blood pressure lowering regimen on cardiac outcomes among patients with cerebrovascular disease. Eur. Heart. J. 24, 475–484 (2003)Google Scholar
- 30.Kuntz, K., Weinstein, M.: Modelling in economic evaluation. In: Drummond, M., McGuire, A. (eds.) Economic Evaluation in Health Care: Merging Theory with Practice. pp. 141–171. OUP, Oxford (2001)Google Scholar
- 31.Collin, C., Wade, D., Davies, S., Horne, V.: The Barthel ADL index: a reliability study. Int. Disabil. Stud. 10(2), 61–63 (1988)Google Scholar
- 32.Caro, J.J., Huybrechts, K.F., Kelley, H.E.: Predicting treatment costs after acute ischemic stroke on the basis of patient characteristics at presentation and early dysfunction. Stroke. 32, 100–106 (2001)Google Scholar
- 34.Chapman, N., Huxley, R., Andersion, C., Bousser, M.G., Chalmers, J., Colman, S., Davis, S., Donnan, G., MacMahon, S., Neal, B., Warlow, C., Woodward, M.: Effects of perindopril-based blood pressure lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS trial. Stroke. 35, 116–121 (2004)CrossRefGoogle Scholar
- 40.Marini, C., Totaro, R., Carolei, A.: Long-term prognosis of cerebral ischemia in young adults. Stroke. 30, 2320–2325 (1999)Google Scholar
- 41.MacWalter, R., Coid, D., Fraser, H., Ersoy, Y.: The Dundee Stroke Register: experience of the first ten years. Scott. Med. J. 44(4), 103–105 (1999)Google Scholar
- 42.Office for National Statistics: Mortality statistics general review of the registrar general on deaths in England and Wales, 2002 Series DH1 no.35. London. 72, Table 8 (2004)Google Scholar
- 44.Scottish Health Statistics: Scottish health service costs NHS national services Scotland, (2004)Google Scholar
- 45.British National Formulary: BMJ Publishing Group Ltd and Royal Pharmaceutical Society of Great Britain, No. 50, (2005)Google Scholar
- 46.Jørgensen, H.S., Nakayama, H., Raaschou, H.O., Olsen, T.S.: Acute stroke care and rehabilitation: an analysis of the direct cost and its clinical and social determinants: the Copenhagen stroke study. Stroke. 28, 1138–1141 (1997)Google Scholar
- 48.Johnson, D.: The triangular distribution as a proxy for the beta distribution in risk analysis. Statistician. 46(3), 387–398 (1997)Google Scholar
- 49.National Institute for Clinical Excellence: Guide to the methods of technology appraisal April 2004 (2004)Google Scholar
- 50.National Institute for Health and Clinical Excellence: Social value judgement—principles for the development of NICE guidance, December (2005). http://www.nice.org.uk/page.aspx?o=283494
- 51.Jonsson, B., Johannesson, M., Kjekshus, J., Olsson, A., Pedersen, T., Wedel, H.: Cost-effectiveness of cholesterol lowering. Results from the scandinavian simvastatin survival study (4S). Eur. Heart. J. 17, 1001–1007 (1996)Google Scholar